{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:26:57Z","timestamp":1790864817849,"version":"4.1.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The liver plays a central role in regulating systemic metabolism, and its function declines with age, contributing to increased susceptibility to metabolic diseases. Metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by hepatic lipid accumulation and inflammation, is an early manifestation of liver dysfunction strongly associated with aging, insulin resistance, and high-fat diet (HFD) consumption. Ames Dwarf mice, which are growth hormone (GH)-deficient and long-lived, retain insulin sensitivity and exhibit resistance to age-related metabolic decline, making them an ideal model to study hepatic protection mechanisms. In this study, male and female Ames Dwarf and wildtype (WT) mice were fed either a standard diet or HFD for 12\u00a0weeks. WT males developed classical features of MASLD, including hepatic steatosis, hepatocyte ballooning, and elevated levels of inflammatory cytokines (IL-1\u03b2, MCP-1, IL-2, and IL-4). In contrast, Ames Dwarf mice exhibited minimal liver pathology, reduced lipid accumulation, and limited cytokine induction. Transcriptomic profiling revealed that WT mice upregulated genes involved in inflammation and proliferation, while Ames Dwarf mice showed activation of protective metabolic pathways (PPAR and AMPK) and suppression of lipogenic and fibrotic gene programs. Notably, female Ames Dwarf mice displayed the strongest resistance to HFD-induced changes, with minimal transcriptomic alterations. These findings suggest that disrupted GH signaling in Ames Dwarf mice leads to a reprogrammed hepatic response that preserves metabolic health and protects against MASLD, highlighting potential links between aging, GH signaling, and liver resilience.<\/jats:p>","DOI":"10.1007\/s11357-025-02017-6","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T02:36:34Z","timestamp":1764210994000},"page":"6647-6692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longevity-driven hepatic transcriptional programs mediate resilience to diet-induced liver injury in Ames dwarf mice"],"prefix":"10.1007","volume":"48","author":[{"given":"Jaspreet Kaur","family":"Osan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene","family":"Rakoczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L.","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7415-4617","authenticated-orcid":false,"given":"Holly M.","family":"Brown-Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2017_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cphy.c130024","volume":"4","author":"L Rui","year":"2014","unstructured":"Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4:177\u201397. https:\/\/doi.org\/10.1002\/cphy.c130024.","journal-title":"Compr Physiol"},{"key":"2017_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-025-1133-7","author":"C Chen","year":"2025","unstructured":"Chen C, Wang L. Aging and metabolic dysfunction-associated steatotic liver disease: a bidirectional relationship. Front Med. 2025. https:\/\/doi.org\/10.1007\/s11684-025-1133-7.","journal-title":"Front Med"},{"key":"2017_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54707.","journal-title":"JAMA Netw Open"},{"key":"2017_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41514-024-00153-5","volume":"10","author":"CH Jones","year":"2024","unstructured":"Jones CH, Dolsten M. Author correction: healthcare on the brink: navigating the challenges of an aging society in the United States. NPJ Aging. 2024;10:25. https:\/\/doi.org\/10.1038\/s41514-024-00153-5.","journal-title":"NPJ Aging"},{"key":"2017_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1097-2765(05)00015-8","volume":"6","author":"MD Michael","year":"2000","unstructured":"Michael MD, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87\u201397.","journal-title":"Mol Cell"},{"key":"2017_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109199","volume":"330","author":"CY Lian","year":"2020","unstructured":"Lian CY, Zhai ZZ, Li ZF, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: a review of proposed mechanisms. Chem Biol Interact. 2020;330:109199. https:\/\/doi.org\/10.1016\/j.cbi.2020.109199.","journal-title":"Chem Biol Interact"},{"key":"2017_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"WK Chan","year":"2023","unstructured":"Chan WK, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32:197\u2013213. https:\/\/doi.org\/10.7570\/jomes23052.","journal-title":"J Obes Metab Syndr"},{"key":"2017_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.601627","volume":"11","author":"A Grefhorst","year":"2020","unstructured":"Grefhorst A, van de Peppel IP, Larsen LE, Jonker JW, Holleboom AG. The role of lipophagy in the development and treatment of non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2020;11:601627. https:\/\/doi.org\/10.3389\/fendo.2020.601627.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2017_CR9","doi-asserted-by":"publisher","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","volume":"6","author":"F Carli","year":"2024","unstructured":"Carli F, Della Pepa G, Sabatini S, Vidal Puig A, Gastaldelli A. Lipid metabolism in MASLD and MASH: from mechanism to the clinic. JHEP Rep. 2024;6:101185. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101185.","journal-title":"JHEP Rep"},{"key":"2017_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3803\/EnM.2024.103","volume":"39","author":"JC Bae","year":"2024","unstructured":"Bae JC. No more NAFLD: the term is now MASLD. Endocrinol Metab. 2024;39:92\u20134. https:\/\/doi.org\/10.3803\/EnM.2024.103.","journal-title":"Endocrinol Metab"},{"key":"2017_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2022;7:851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2017_CR12","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa134","author":"JK DiStefano","year":"2020","unstructured":"DiStefano JK. NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment. Endocrinology. 2020. https:\/\/doi.org\/10.1210\/endocr\/bqaa134.","journal-title":"Endocrinology"},{"key":"2017_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1139\/h11-153","volume":"37","author":"MC Louwe","year":"2012","unstructured":"Louwe MC, et al. Gender-dependent effects of high-fat lard diet on cardiac function in C57Bl\/6J mice. Appl Physiol Nutr Metab. 2012;37:214\u201324. https:\/\/doi.org\/10.1139\/h11-153.","journal-title":"Appl Physiol Nutr Metab"},{"key":"2017_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107795","volume":"35","author":"I Casimiro","year":"2021","unstructured":"Casimiro I, Stull ND, Tersey SA, Mirmira RG. Phenotypic sexual dimorphism in response to dietary fat manipulation in C57BL\/6J mice. J Diabetes Complications. 2021;35:107795. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107795.","journal-title":"J Diabetes Complications"},{"key":"2017_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70765-w","volume":"10","author":"MS Siersbaek","year":"2020","unstructured":"Siersbaek MS, et al. C57BL\/6J substrain differences in response to high-fat diet intervention. Sci Rep. 2020;10:14052. https:\/\/doi.org\/10.1038\/s41598-020-70765-w.","journal-title":"Sci Rep"},{"key":"2017_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-319-70178-3_12","volume":"1043","author":"BT Palmisano","year":"2017","unstructured":"Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol. 2017;1043:227\u201356. https:\/\/doi.org\/10.1007\/978-3-319-70178-3_12.","journal-title":"Adv Exp Med Biol"},{"key":"2017_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.5604\/16652681.1235481","volume":"16","author":"V Jaruvongvanich","year":"2017","unstructured":"Jaruvongvanich V, Sanguankeo A, Riangwiwat T, Upala S. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol. 2017;16:382\u201394. https:\/\/doi.org\/10.5604\/16652681.1235481.","journal-title":"Ann Hepatol"},{"key":"2017_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41574-024-01037-0","volume":"21","author":"RD Kineman","year":"2025","unstructured":"Kineman RD, Del Rio-Moreno M, Waxman DJ. Liver-specific actions of GH and IGF1 that protect against MASLD. Nat Rev Endocrinol. 2025;21:105\u201317. https:\/\/doi.org\/10.1038\/s41574-024-01037-0.","journal-title":"Nat Rev Endocrinol"},{"key":"2017_CR19","doi-asserted-by":"publisher","first-page":"e3624","DOI":"10.1210\/clinem\/dgac405","volume":"107","author":"LE Dichtel","year":"2022","unstructured":"Dichtel LE, et al. The GH\/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight\/obesity. J Clin Endocrinol Metab. 2022;107:e3624\u201332. https:\/\/doi.org\/10.1210\/clinem\/dgac405.","journal-title":"J Clin Endocrinol Metab"},{"key":"2017_CR20","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001924RR","volume":"35","author":"Z Huang","year":"2021","unstructured":"Huang Z, et al. Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice. FASEB J. 2021;35:e21269. https:\/\/doi.org\/10.1096\/fj.202001924RR.","journal-title":"FASEB J"},{"key":"2017_CR21","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.2337\/db15-0370","volume":"64","author":"J Cordoba-Chacon","year":"2015","unstructured":"Cordoba-Chacon J, et al. Growth hormone inhibits hepatic de novo lipogenesis in adult mice. Diabetes. 2015;64:3093\u2013103. https:\/\/doi.org\/10.2337\/db15-0370.","journal-title":"Diabetes"},{"key":"2017_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155589","volume":"144","author":"MC Vazquez-Borrego","year":"2023","unstructured":"Vazquez-Borrego MC, et al. Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis. Metabolism. 2023;144:155589. https:\/\/doi.org\/10.1016\/j.metabol.2023.155589.","journal-title":"Metabolism"},{"key":"2017_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14238","volume":"23","author":"J Adkins-Jablonsky","year":"2024","unstructured":"Adkins-Jablonsky J, Lasher AT, Patki A, Nagarajan A, Sun LY. Growth hormone-releasing hormone deficiency confers extended lifespan and metabolic resilience during high-fat feeding in mid and late life. Aging Cell. 2024;23:e14238. https:\/\/doi.org\/10.1111\/acel.14238.","journal-title":"Aging Cell"},{"key":"2017_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/384033a0","volume":"384","author":"HM Brown-Borg","year":"1996","unstructured":"Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process. Nature. 1996;384:33. https:\/\/doi.org\/10.1038\/384033a0.","journal-title":"Nature"},{"key":"2017_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/acel.12467","volume":"15","author":"CM Hill","year":"2016","unstructured":"Hill CM, et al. Long-lived hypopituitary Ames dwarf mice are resistant to the detrimental effects of high-fat diet on metabolic function and energy expenditure. Aging Cell. 2016;15:509\u201321. https:\/\/doi.org\/10.1111\/acel.12467.","journal-title":"Aging Cell"},{"key":"2017_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-014-9709-1","volume":"36","author":"DS Wiesenborn","year":"2014","unstructured":"Wiesenborn DS, Ayala JE, King E, Masternak MM. Insulin sensitivity in long-living Ames dwarf mice. AGE. 2014;36:9709. https:\/\/doi.org\/10.1007\/s11357-014-9709-1.","journal-title":"AGE"},{"key":"2017_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071447","author":"Y Takahashi","year":"2017","unstructured":"Takahashi Y. The role of growth hormone and insulin-like growth factor-I in the liver. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18071447.","journal-title":"Int J Mol Sci"},{"key":"2017_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"key":"2017_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2023.102466","volume":"4","author":"A Nishad","year":"2023","unstructured":"Nishad A, Naseem A, Rani S, Malik S. Automated qualitative batch measurement of lipid droplets in the liver of bird using imagej. STAR Protoc. 2023;4:102466. https:\/\/doi.org\/10.1016\/j.xpro.2023.102466.","journal-title":"STAR Protoc"},{"key":"2017_CR30","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2020","unstructured":"Ge SX, Jung D, Yao R. Shinygo: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36:2628\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btz931.","journal-title":"Bioinformatics"},{"key":"2017_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107265","volume":"9","author":"KA Negrin","year":"2014","unstructured":"Negrin KA, et al. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One. 2014;9:e107265. https:\/\/doi.org\/10.1371\/journal.pone.0107265.","journal-title":"PLoS One"},{"key":"2017_CR32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.yexmp.2011.08.001","volume":"91","author":"G Kirovski","year":"2011","unstructured":"Kirovski G, et al. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation. Exp Mol Pathol. 2011;91:780\u20133. https:\/\/doi.org\/10.1016\/j.yexmp.2011.08.001.","journal-title":"Exp Mol Pathol"},{"key":"2017_CR33","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbadis.2013.06.001","volume":"1832","author":"YA Nevzorova","year":"2013","unstructured":"Nevzorova YA, et al. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta. 2013;1832:1765\u201375. https:\/\/doi.org\/10.1016\/j.bbadis.2013.06.001.","journal-title":"Biochim Biophys Acta"},{"key":"2017_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12967-024-04942-0","volume":"22","author":"J Dong","year":"2024","unstructured":"Dong J, et al. Acaca reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARalpha- CPT1A axis. J Transl Med. 2024;22:196. https:\/\/doi.org\/10.1186\/s12967-024-04942-0.","journal-title":"J Transl Med"},{"key":"2017_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41388-018-0442-6","volume":"38","author":"CY Lai","year":"2019","unstructured":"Lai CY, et al. Identification of UAP1L1 as a critical factor for protein O-GlcNAcylation and cell proliferation in human hepatoma cells. Oncogene. 2019;38:317\u201331. https:\/\/doi.org\/10.1038\/s41388-018-0442-6.","journal-title":"Oncogene"},{"key":"2017_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.106004","volume":"175","author":"X Tao","year":"2022","unstructured":"Tao X, et al. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-\u03b21 pathway: therapeutic role of roflumilast. Pharmacol Res. 2022;175:106004. https:\/\/doi.org\/10.1016\/j.phrs.2021.106004.","journal-title":"Pharmacol Res"},{"key":"2017_CR37","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202063","author":"J Chen","year":"2021","unstructured":"Chen J, et al. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep. 2021. https:\/\/doi.org\/10.1042\/BSR20202063.","journal-title":"Biosci Rep"},{"key":"2017_CR38","doi-asserted-by":"publisher","unstructured":"Jiang J, et al. Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. Cell Metab 2025;37:1119\u20131136 e1113. https:\/\/doi.org\/10.1016\/j.cmet.2025.01.016.","DOI":"10.1016\/j.cmet.2025.01.016"},{"key":"2017_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108298","volume":"240","author":"SM Ishtiaq","year":"2022","unstructured":"Ishtiaq SM, Arshad MI, Khan JA. PPARgamma signaling in hepatocarcinogenesis: mechanistic insights for cellular reprogramming and therapeutic implications. Pharmacol Ther. 2022;240:108298. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108298.","journal-title":"Pharmacol Ther"},{"key":"2017_CR40","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1038\/s41598-025-86810-5","volume":"15","author":"Q Li","year":"2025","unstructured":"Li Q, et al. Polystyrene microplastics induce liver fibrosis and lipid deposition in mice through three hub genes revealed by the RNA-seq. Sci Rep. 2025;15:2583. https:\/\/doi.org\/10.1038\/s41598-025-86810-5.","journal-title":"Sci Rep"},{"key":"2017_CR41","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1038\/s41598-019-43928-7","volume":"9","author":"A Sans","year":"2019","unstructured":"Sans A, et al. The differential expression of Cide family members is associated with NAFLD progression from steatosis to steatohepatitis. Sci Rep. 2019;9:7501. https:\/\/doi.org\/10.1038\/s41598-019-43928-7.","journal-title":"Sci Rep"},{"key":"2017_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-023-00754-4","volume":"18","author":"DB Ping","year":"2023","unstructured":"Ping DB, Sun X, Peng Y, Liu CH. Cyp4a12-mediated retinol metabolism in stellate cells is the antihepatic fibrosis mechanism of the Chinese medicine Fuzheng Huayu recipe. Chin Med. 2023;18:51. https:\/\/doi.org\/10.1186\/s13020-023-00754-4.","journal-title":"Chin Med"},{"key":"2017_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2024.159538","volume":"1869","author":"JN Ntambi","year":"2024","unstructured":"Ntambi JN, et al. Hepatic stearoyl-CoA desaturase-1 deficiency induces fibrosis and hepatocellular carcinoma-related gene activation under a high carbohydrate low fat diet. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2024;1869:159538. https:\/\/doi.org\/10.1016\/j.bbalip.2024.159538.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"},{"key":"2017_CR44","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.bbrc.2020.04.077","volume":"527","author":"LM O\u2019Neill","year":"2020","unstructured":"O\u2019Neill LM, et al. Global deficiency of stearoyl-CoA desaturase-2 protects against diet-induced adiposity. Biochem Biophys Res Commun. 2020;527:589\u201395. https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.077.","journal-title":"Biochem Biophys Res Commun"},{"key":"2017_CR45","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300433RR","volume":"37","author":"J Liu","year":"2023","unstructured":"Liu J, et al. Farnesyl diphosphate synthase exacerbates nonalcoholic steatohepatitis via the activation of AHR-CD36 axis. FASEB J. 2023;37:e23035. https:\/\/doi.org\/10.1096\/fj.202300433RR.","journal-title":"FASEB J"},{"key":"2017_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1196\/annals.1297.053","volume":"1019","author":"HM Brown-Borg","year":"2004","unstructured":"Brown-Borg HM, Rakoczy SG, Uthus EO. Growth hormone alters components of the glutathione metabolic pathway in Ames dwarf mice. Ann N Y Acad Sci. 2004;1019:317\u201320. https:\/\/doi.org\/10.1196\/annals.1297.053.","journal-title":"Ann N Y Acad Sci"},{"key":"2017_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100326","volume":"24","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Growth hormone attenuates obesity and reshapes gut microbiota in high-fat diet-fed mice. Metab Open. 2024;24:100326. https:\/\/doi.org\/10.1016\/j.metop.2024.100326.","journal-title":"Metab Open"},{"key":"2017_CR48","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/hep.26465","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin M, et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644\u201354. https:\/\/doi.org\/10.1002\/hep.26465.","journal-title":"Hepatology"},{"issue":"1","key":"2017_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26896-3","volume":"13","author":"D Kucsera","year":"2023","unstructured":"Kucsera D, et al. <article-title update=\"added\">IL-1\u03b2 neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH. Sci Rep. 2023;13(1):356. https:\/\/doi.org\/10.1038\/s41598-022-26896-3.","journal-title":"Sci Rep"},{"key":"2017_CR50","doi-asserted-by":"publisher","unstructured":"Kern L, et al. Obesity-induced TNFalpha and IL-6 signaling: the missing link between obesity and inflammation-driven liver and colorectal cancers. Cancers (Basel) 2018; 11. https:\/\/doi.org\/10.3390\/cancers11010024.","DOI":"10.3390\/cancers11010024"},{"key":"2017_CR51","doi-asserted-by":"publisher","first-page":"G663","DOI":"10.1152\/ajpgi.00070.2007","volume":"293","author":"AL Patrick","year":"2007","unstructured":"Patrick AL, Rullo J, Beaudin S, Liaw P, Fox-Robichaud AE. Hepatic leukocyte recruitment in response to time-limited expression of TNF-alpha and IL-1beta. Am J Physiol Gastrointest Liver Physiol. 2007;293:G663-672. https:\/\/doi.org\/10.1152\/ajpgi.00070.2007.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2017_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14030153","author":"S Rafaqat","year":"2024","unstructured":"Rafaqat S, Gluscevic S, Mercantepe F, Rafaqat S, Klisic A. Interleukins: pathogenesis in non-alcoholic fatty liver disease. Metabolites. 2024. https:\/\/doi.org\/10.3390\/metabo14030153.","journal-title":"Metabolites"},{"key":"2017_CR53","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jcmgh.2021.01.003","volume":"11","author":"SM Lee","year":"2021","unstructured":"Lee SM, et al. Hepatocyte-specific loss of PPARgamma protects mice from NASH and increases the therapeutic effects of rosiglitazone in the liver. Cell Mol Gastroenterol Hepatol. 2021;11:1291\u2013311. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.01.003.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2017_CR54","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/01.CCM.0000109453.57709.E2","volume":"32","author":"JH Crawford","year":"2004","unstructured":"Crawford JH, Yang S, Zhou M, Simms HH, Wang P. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med. 2004;32:502\u20138. https:\/\/doi.org\/10.1097\/01.CCM.0000109453.57709.E2.","journal-title":"Crit Care Med"},{"key":"2017_CR55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.bbalip.2015.12.019","volume":"1861","author":"R Mysore","year":"2016","unstructured":"Mysore R, et al. Microrna-192* impairs adipocyte triglyceride storage. Biochim Biophys Acta. 2016;1861:342\u201351. https:\/\/doi.org\/10.1016\/j.bbalip.2015.12.019.","journal-title":"Biochim Biophys Acta"},{"key":"2017_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijbiomac.2022.06.077","volume":"215","author":"S He","year":"2022","unstructured":"He S, et al. Lotus seed resistant starch ameliorates high-fat diet induced hyperlipidemia by fatty acid degradation and glycerolipid metabolism pathways in mouse liver. Int J Biol Macromol. 2022;215:79\u201391. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.06.077.","journal-title":"Int J Biol Macromol"},{"key":"2017_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2022.136543","volume":"308","author":"H Cui","year":"2022","unstructured":"Cui H, Chang Y, Cao J, Jiang X, Li M. Liver immune and lipid metabolism disorders in mice induced by triphenyl phosphate with or without high fructose and high fat diet. Chemosphere. 2022;308:136543. https:\/\/doi.org\/10.1016\/j.chemosphere.2022.136543.","journal-title":"Chemosphere"},{"key":"2017_CR58","first-page":"1443","volume":"12","author":"H Zhu","year":"2020","unstructured":"Zhu H, et al. pSTAT3 Y705 is a prognostic biomarker identified from time-series gene expression profiles of a chemically induced mouse model of hepatocellular carcinoma. Am J Transl Res. 2020;12:1443\u201358.","journal-title":"Am J Transl Res"},{"key":"2017_CR59","doi-asserted-by":"publisher","unstructured":"O'Neill LM, et al. Stearoyl-CoA desaturase-2 in murine development, metabolism, and disease. Int J Mol Sci 2020; 21. https:\/\/doi.org\/10.3390\/ijms21228619.","DOI":"10.3390\/ijms21228619"},{"key":"2017_CR60","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2337\/db13-0788","volume":"63","author":"S Chen","year":"2014","unstructured":"Chen S, et al. Vanin-1 is a key activator for hepatic gluconeogenesis. Diabetes. 2014;63:2073\u201385. https:\/\/doi.org\/10.2337\/db13-0788.","journal-title":"Diabetes"},{"key":"2017_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176220","volume":"962","author":"H Yu","year":"2024","unstructured":"Yu H, et al. Vanin1 (VNN1) in chronic diseases: future directions for targeted therapy. Eur J Pharmacol. 2024;962:176220. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176220.","journal-title":"Eur J Pharmacol"},{"key":"2017_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.molimm.2015.06.001","volume":"67","author":"SM Moore","year":"2015","unstructured":"Moore SM, Holt VV, Malpass LR, Hines IN, Wheeler MD. Fatty acid-binding protein 5 limits the anti-inflammatory response in murine macrophages. Mol Immunol. 2015;67:265\u201375. https:\/\/doi.org\/10.1016\/j.molimm.2015.06.001.","journal-title":"Mol Immunol"},{"key":"2017_CR63","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.3748\/wjg.14.2888","volume":"14","author":"XD Huang","year":"2008","unstructured":"Huang XD, et al. Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol. 2008;14:2888\u201393. https:\/\/doi.org\/10.3748\/wjg.14.2888.","journal-title":"World J Gastroenterol"},{"key":"2017_CR64","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1210\/me.2006-0007","volume":"20","author":"DJ Waxman","year":"2006","unstructured":"Waxman DJ, O\u2019Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006;20:2613\u201329. https:\/\/doi.org\/10.1210\/me.2006-0007.","journal-title":"Mol Endocrinol"},{"key":"2017_CR65","doi-asserted-by":"publisher","first-page":"26158","DOI":"10.1021\/acsomega.3c02347","volume":"8","author":"J Guo","year":"2023","unstructured":"Guo J, et al. Hepatic Clstn3 ameliorates lipid metabolism disorders in high fat diet-induced NAFLD through activation of FXR. ACS Omega. 2023;8:26158\u201369. https:\/\/doi.org\/10.1021\/acsomega.3c02347.","journal-title":"ACS Omega"},{"key":"2017_CR66","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.livres.2018.12.001","volume":"2","author":"YK Lee","year":"2018","unstructured":"Lee YK, Park JE, Lee M, Hardwick JP. Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. Liver Res. 2018;2:209\u201315. https:\/\/doi.org\/10.1016\/j.livres.2018.12.001.","journal-title":"Liver Res"},{"key":"2017_CR67","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.2337\/db16-1519","volume":"66","author":"MP Franklin","year":"2017","unstructured":"Franklin MP, Sathyanarayan A, Mashek DG. Acyl-CoA thioesterase 1 (ACOT1) regulates PPARalpha to couple fatty acid flux with oxidative capacity during fasting. Diabetes. 2017;66:2112\u201323. https:\/\/doi.org\/10.2337\/db16-1519.","journal-title":"Diabetes"},{"key":"2017_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115586","volume":"170","author":"Q Sun","year":"2024","unstructured":"Sun Q, et al. SCD1 is the critical signaling hub to mediate metabolic diseases: mechanism and the development of its inhibitors. Biomed Pharmacother. 2024;170:115586. https:\/\/doi.org\/10.1016\/j.biopha.2023.115586.","journal-title":"Biomed Pharmacother"},{"key":"2017_CR69","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12964-023-01297-9","volume":"21","author":"W Wang","year":"2023","unstructured":"Wang W, et al. Identification of novel SCD1 inhibitor alleviates nonalcoholic fatty liver disease: critical role of liver-adipose axis. Cell Commun Signal. 2023;21:268. https:\/\/doi.org\/10.1186\/s12964-023-01297-9.","journal-title":"Cell Commun Signal"},{"key":"2017_CR70","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41366-018-0062-9","volume":"42","author":"M Honma","year":"2018","unstructured":"Honma M, et al. Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers. Int J Obes (Lond). 2018;42:1544\u201355. https:\/\/doi.org\/10.1038\/s41366-018-0062-9.","journal-title":"Int J Obes (Lond)"},{"key":"2017_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020252","author":"EA Bates","year":"2023","unstructured":"Bates EA, et al. Suppressing hepatic UGT1A1 increases plasma bilirubin, lowers plasma urobilin, reorganizes kinase signaling pathways and lipid species and improves fatty liver disease. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13020252.","journal-title":"Biomolecules"},{"key":"2017_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.592573","volume":"8","author":"L Gatticchi","year":"2020","unstructured":"Gatticchi L, et al. Tm7sf2 disruption alters radial gene positioning in mouse liver leading to metabolic defects and diabetes characteristics. Front Cell Dev Biol. 2020;8:592573. https:\/\/doi.org\/10.3389\/fcell.2020.592573.","journal-title":"Front Cell Dev Biol"},{"key":"2017_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101230","volume":"7","author":"A Lamas-Paz","year":"2025","unstructured":"Lamas-Paz A, et al. Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis. JHEP Rep. 2025;7:101230. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101230.","journal-title":"JHEP Rep"},{"key":"2017_CR74","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bbrc.2023.03.075","volume":"658","author":"Z Qin","year":"2023","unstructured":"Qin Z, et al. Hepatic ELOVL3 is dispensable for lipid metabolism in mice. Biochem Biophys Res Commun. 2023;658:128\u201335. https:\/\/doi.org\/10.1016\/j.bbrc.2023.03.075.","journal-title":"Biochem Biophys Res Commun"},{"key":"2017_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/genes8040123","author":"K Zheng","year":"2017","unstructured":"Zheng K, Cubero FJ, Nevzorova YA. C-MYC-making liver sick: role of c-MYC in hepatic cell function, homeostasis and disease. Genes. 2017. https:\/\/doi.org\/10.3390\/genes8040123.","journal-title":"Genes"},{"key":"2017_CR76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0065-2571(92)90021-q","volume":"32","author":"A Mode","year":"1992","unstructured":"Mode A, et al. Growth hormone regulation of hepatic cytochrome P450 expression in the rat. Adv Enzyme Regul. 1992;32:255\u201363. https:\/\/doi.org\/10.1016\/0065-2571(92)90021-q.","journal-title":"Adv Enzyme Regul"},{"key":"2017_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1425528","volume":"11","author":"C Thomas","year":"2024","unstructured":"Thomas C, Njoku DB. Sexual dimorphism in hepatic PPAR alpha and CYP4a12a expression is associated with reduced development of drug-induced non-alcoholic steatohepatitis in female IL-33(-\/-) mice. Front Med (Lausanne). 2024;11:1425528. https:\/\/doi.org\/10.3389\/fmed.2024.1425528.","journal-title":"Front Med (Lausanne)"},{"key":"2017_CR78","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1073\/pnas.1700172114","volume":"114","author":"X Zhang","year":"2017","unstructured":"Zhang X, et al. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc Natl Acad Sci U S A. 2017;114:3181\u20135. https:\/\/doi.org\/10.1073\/pnas.1700172114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2017_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-8-353","volume":"8","author":"WR Swindell","year":"2007","unstructured":"Swindell WR. Gene expression profiling of long-lived dwarf mice: longevity-associated genes and relationships with diet, gender and aging. BMC Genomics. 2007;8:353. https:\/\/doi.org\/10.1186\/1471-2164-8-353.","journal-title":"BMC Genomics"},{"key":"2017_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111960","volume":"134","author":"J Guo","year":"2025","unstructured":"Guo J, et al. The FMO3\/TMAO\/HSP90\u03b2 axis aggravates MAFLD by disrupting mitochondrial protein homeostasis. Cell Signal. 2025;134:111960. https:\/\/doi.org\/10.1016\/j.cellsig.2025.111960.","journal-title":"Cell Signal"},{"key":"2017_CR81","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.celrep.2017.05.077","volume":"19","author":"RC Schugar","year":"2017","unstructured":"Schugar RC, et al. The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue. Cell Rep. 2017;19:2451\u201361. https:\/\/doi.org\/10.1016\/j.celrep.2017.05.077.","journal-title":"Cell Rep"},{"key":"2017_CR82","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1124\/dmd.111.041012","volume":"39","author":"RN Hardwick","year":"2011","unstructured":"Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39:2395\u2013402. https:\/\/doi.org\/10.1124\/dmd.111.041012.","journal-title":"Drug Metab Dispos"},{"key":"2017_CR83","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/s42003-025-08818-x","volume":"8","author":"J Chen","year":"2025","unstructured":"Chen J, et al. ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver. Commun Biol. 2025;8:1414. https:\/\/doi.org\/10.1038\/s42003-025-08818-x.","journal-title":"Commun Biol"},{"key":"2017_CR84","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1194\/jlr.M046961","volume":"55","author":"C Moffat","year":"2014","unstructured":"Moffat C, et al. Acyl-CoA thioesterase-2 facilitates mitochondrial fatty acid oxidation in the liver. J Lipid Res. 2014;55:2458\u201370. https:\/\/doi.org\/10.1194\/jlr.M046961.","journal-title":"J Lipid Res"},{"key":"2017_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27618","volume":"10","author":"Q Yuan","year":"2024","unstructured":"Yuan Q, et al. Knockdown of ACOT4 alleviates gluconeogenesis and lipid accumulation in hepatocytes. Heliyon. 2024;10:e27618. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27618.","journal-title":"Heliyon"},{"key":"2017_CR86","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/hep.30097","volume":"68","author":"L Goedeke","year":"2018","unstructured":"Goedeke L, et al. Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology. 2018;68:2197\u2013211. https:\/\/doi.org\/10.1002\/hep.30097.","journal-title":"Hepatology"},{"key":"2017_CR87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12944-025-02491-z","volume":"24","author":"A El-Kurjieh","year":"2025","unstructured":"El-Kurjieh A, Al-Arab R, Hachem QA, Ibrahim JN, Kobeissy PH. ACSS2 and metabolic diseases: from lipid metabolism to therapeutic target. Lipids Health Dis. 2025;24:74. https:\/\/doi.org\/10.1186\/s12944-025-02491-z.","journal-title":"Lipids Health Dis"},{"key":"2017_CR88","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jhep.2024.08.009","volume":"82","author":"YJ Liu","year":"2025","unstructured":"Liu YJ, et al. ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD\/MASH. J Hepatol. 2025;82:174\u201388. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.009.","journal-title":"J Hepatol"},{"key":"2017_CR89","doi-asserted-by":"publisher","first-page":"921","DOI":"10.7150\/ijbs.42300","volume":"16","author":"W Wang","year":"2020","unstructured":"Wang W, Wang C, Xu H, Gao Y. Aldehyde dehydrogenase, liver disease and cancer. Int J Biol Sci. 2020;16:921\u201334. https:\/\/doi.org\/10.7150\/ijbs.42300.","journal-title":"Int J Biol Sci"},{"key":"2017_CR90","doi-asserted-by":"publisher","first-page":"1569927","DOI":"10.3389\/fphar.2025.1569927","volume":"16","author":"M Feng","year":"2025","unstructured":"Feng M, He Y, Wang H. Role of the annexin A protein family in liver diseases: insights and therapeutic opportunities. Front Pharmacol. 2025;16:1569927. https:\/\/doi.org\/10.3389\/fphar.2025.1569927.","journal-title":"Front Pharmacol"},{"key":"2017_CR91","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1530\/EC-21-0353","volume":"10","author":"X Chen","year":"2021","unstructured":"Chen X, Tang Y, Chen S, Ling W, Wang Q. IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study. Endocr Connect. 2021;10:1315\u201325. https:\/\/doi.org\/10.1530\/EC-21-0353.","journal-title":"Endocr Connect"},{"key":"2017_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102119","volume":"95","author":"AM Lundsgaard","year":"2025","unstructured":"Lundsgaard AM, et al. Apolipoprotein A-IV is induced by high-fat diets and mediates positive effects on glucose and lipid metabolism. Mol Metab. 2025;95:102119. https:\/\/doi.org\/10.1016\/j.molmet.2025.102119.","journal-title":"Mol Metab"},{"key":"2017_CR93","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501007R","volume":"39","author":"X Luo","year":"2025","unstructured":"Luo X, et al. Hydronidone alleviates metabolic dysfunction-associated fatty liver disease by inhibiting CD36 expression. FASEB J. 2025;39:e70800. https:\/\/doi.org\/10.1096\/fj.202501007R.","journal-title":"FASEB J"},{"key":"2017_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002728","volume":"22","author":"H Jun","year":"2024","unstructured":"Jun H, et al. Signaling through the nicotinic acetylcholine receptor in the liver protects against the development of metabolic dysfunction-associated steatohepatitis. PLoS Biol. 2024;22:e3002728. https:\/\/doi.org\/10.1371\/journal.pbio.3002728.","journal-title":"PLoS Biol"},{"key":"2017_CR95","doi-asserted-by":"publisher","unstructured":"Pan C, et al. Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. Cell Metab 2023;35:2231\u20132249 e2237. https:\/\/doi.org\/10.1016\/j.cmet.2023.10.018.","DOI":"10.1016\/j.cmet.2023.10.018"},{"key":"2017_CR96","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11010-014-1995-5","volume":"391","author":"T Hussain","year":"2014","unstructured":"Hussain T, et al. Induction of CYP1A1, CYP1A2, CYP1B1, increased oxidative stress and inflammation in the lung and liver tissues of rats exposed to incense smoke. Mol Cell Biochem. 2014;391:127\u201336. https:\/\/doi.org\/10.1007\/s11010-014-1995-5.","journal-title":"Mol Cell Biochem"},{"key":"2017_CR97","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12964-023-01061-z","volume":"21","author":"TT Wu","year":"2023","unstructured":"Wu TT, et al. Mutated CYP17A1 promotes atherosclerosis and early-onset coronary artery disease. Cell Commun Signal. 2023;21:155. https:\/\/doi.org\/10.1186\/s12964-023-01061-z.","journal-title":"Cell Commun Signal"},{"key":"2017_CR98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.etap.2016.05.014","volume":"45","author":"C Wang","year":"2016","unstructured":"Wang C, Tao Q, Wang X, Wang X, Zhang X. Impact of high-fat diet on liver genes expression profiles in mice model of nonalcoholic fatty liver disease. Environ Toxicol Pharmacol. 2016;45:52\u201362. https:\/\/doi.org\/10.1016\/j.etap.2016.05.014.","journal-title":"Environ Toxicol Pharmacol"},{"key":"2017_CR99","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.1039\/d0fo02123g","volume":"11","author":"Y Lu","year":"2020","unstructured":"Lu Y, et al. Integrative transcriptomics and metabolomics explore the mechanism of kaempferol on improving nonalcoholic steatohepatitis. Food Funct. 2020;11:10058\u201369. https:\/\/doi.org\/10.1039\/d0fo02123g.","journal-title":"Food Funct"},{"key":"2017_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229896","volume":"15","author":"MM Heintz","year":"2020","unstructured":"Heintz MM, McRee R, Kumar R, Baldwin WS. Gender differences in diet-induced steatotic disease in Cyp2b-null mice. PLoS ONE. 2020;15:e0229896. https:\/\/doi.org\/10.1371\/journal.pone.0229896.","journal-title":"PLoS ONE"},{"key":"2017_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/srep08777","volume":"5","author":"G Lorbek","year":"2015","unstructured":"Lorbek G, et al. Lessons from hepatocyte-specific Cyp51 knockout mice: impaired cholesterol synthesis leads to oval cell-driven liver injury. Sci Rep. 2015;5:8777. https:\/\/doi.org\/10.1038\/srep08777.","journal-title":"Sci Rep"},{"key":"2017_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2025.100757","volume":"66","author":"G Kakiyama","year":"2025","unstructured":"Kakiyama G, et al. Liver specific transgenic expression of CYP7B1 attenuates early western diet-induced MASLD progression. J Lipid Res. 2025;66:100757. https:\/\/doi.org\/10.1016\/j.jlr.2025.100757.","journal-title":"J Lipid Res"},{"key":"2017_CR103","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1194\/jlr.M092544","volume":"60","author":"J Lian","year":"2019","unstructured":"Lian J, et al. Ces1d deficiency protects against high-sucrose diet-induced hepatic triacylglycerol accumulation. J Lipid Res. 2019;60:880\u201391. https:\/\/doi.org\/10.1194\/jlr.M092544.","journal-title":"J Lipid Res"},{"key":"2017_CR104","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbalip.2016.03.009","volume":"1861","author":"W Bahitham","year":"2016","unstructured":"Bahitham W, Watts R, Nelson R, Lian J, Lehner R. Liver-specific expression of carboxylesterase 1g\/esterase-x reduces hepatic steatosis, counteracts dyslipidemia and improves insulin signaling. Biochim Biophys Acta. 2016;1861:482\u201390. https:\/\/doi.org\/10.1016\/j.bbalip.2016.03.009.","journal-title":"Biochim Biophys Acta"},{"key":"2017_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2025.100887","volume":"66","author":"Z Batayneh","year":"2025","unstructured":"Batayneh Z, et al. Loss of hepatic carboxylesterase 3 prevents the development of MASLD in mice. J Lipid Res. 2025;66:100887. https:\/\/doi.org\/10.1016\/j.jlr.2025.100887.","journal-title":"J Lipid Res"},{"key":"2017_CR106","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.7150\/ijbs.97008","volume":"21","author":"P Chan","year":"2025","unstructured":"Chan P, et al. Cgref1 is a CREB-H-regulated hepatokine that promotes hepatic de novo lipogenesis by mediating epididymal fat insulin resistance. Int J Biol Sci. 2025;21:2568\u201388. https:\/\/doi.org\/10.7150\/ijbs.97008.","journal-title":"Int J Biol Sci"},{"key":"2017_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01413-5","volume":"15","author":"Z Tang","year":"2023","unstructured":"Tang Z, Yang Y, Zhang Q, Liang T. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients. Clin Epigenetics. 2023;15:13. https:\/\/doi.org\/10.1186\/s13148-022-01413-5.","journal-title":"Clin Epigenetics"},{"key":"2017_CR108","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.26898","volume":"59","author":"BC Fuchs","year":"2014","unstructured":"Fuchs BC, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59:1577\u201390. https:\/\/doi.org\/10.1002\/hep.26898.","journal-title":"Hepatology"},{"key":"2017_CR109","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/002215540004800610","volume":"48","author":"LG Komuves","year":"2000","unstructured":"Komuves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000;48:821\u201330. https:\/\/doi.org\/10.1177\/002215540004800610.","journal-title":"J Histochem Cytochem"},{"key":"2017_CR110","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05420-y","volume":"81","author":"F Sun","year":"2024","unstructured":"Sun F, et al. Epitranscriptomic regulation of lipid oxidation and liver fibrosis via ENPP1 mRNA m(6)a modification. Cell Mol Life Sci. 2024;81:387. https:\/\/doi.org\/10.1007\/s00018-024-05420-y.","journal-title":"Cell Mol Life Sci"},{"key":"2017_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/srep17604","volume":"5","author":"M Kuba","year":"2015","unstructured":"Kuba M, et al. Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-\/-) mouse model. Sci Rep. 2015;5:17604. https:\/\/doi.org\/10.1038\/srep17604.","journal-title":"Sci Rep"},{"key":"2017_CR112","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/hep.25932","volume":"56","author":"T Matsuzaka","year":"2012","unstructured":"Matsuzaka T, et al. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology. 2012;56:2199\u2013208. https:\/\/doi.org\/10.1002\/hep.25932.","journal-title":"Hepatology"},{"key":"2017_CR113","doi-asserted-by":"publisher","unstructured":"K AE, et al. The emerging role of ethanolamine phosphate phospholyase in regulating hepatic phosphatidylethanolamine and plasma lipoprotein metabolism in mice. FASEB J 2024;38:e70063. https:\/\/doi.org\/10.1096\/fj.202401321R.","DOI":"10.1096\/fj.202401321R"},{"key":"2017_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1066410","volume":"14","author":"F Yang","year":"2023","unstructured":"Yang F, et al. Key genes associated with non-alcoholic fatty liver disease and hepatocellular carcinoma with metabolic risk factors. Front Genet. 2023;14:1066410. https:\/\/doi.org\/10.3389\/fgene.2023.1066410.","journal-title":"Front Genet"},{"key":"2017_CR115","doi-asserted-by":"publisher","unstructured":"Gliniak CM, et al. FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression. Cell Metab 2025;37:1547\u20131567 e1546. https:\/\/doi.org\/10.1016\/j.cmet.2025.05.011.","DOI":"10.1016\/j.cmet.2025.05.011"},{"key":"2017_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.601290","volume":"11","author":"EJ Tillman","year":"2020","unstructured":"Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne). 2020;11:601290. https:\/\/doi.org\/10.3389\/fendo.2020.601290.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2017_CR117","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41374-021-00680-9","volume":"102","author":"K Yano","year":"2022","unstructured":"Yano K, et al. Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice. Lab Invest. 2022;102:281\u20139. https:\/\/doi.org\/10.1038\/s41374-021-00680-9.","journal-title":"Lab Invest"},{"key":"2017_CR118","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/HEP.0000000000000643","volume":"81","author":"C Ke","year":"2025","unstructured":"Ke C, et al. FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. Hepatology. 2025;81:181\u201397. https:\/\/doi.org\/10.1097\/HEP.0000000000000643.","journal-title":"Hepatology"},{"key":"2017_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123699","volume":"374","author":"H Zhang","year":"2025","unstructured":"Zhang H, et al. FMO3 exacerbates hepatic endoplasmic reticulum stress in drug-induced liver injury by inhibiting CREB3\/P4HB axis and activating TMAO-mediated PERK pathway. Life Sci. 2025;374:123699. https:\/\/doi.org\/10.1016\/j.lfs.2025.123699.","journal-title":"Life Sci"},{"key":"2017_CR120","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.humpath.2005.07.017","volume":"36","author":"L Gramantieri","year":"2005","unstructured":"Gramantieri L, et al. GADD45-\u03b1 expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation. Hum Pathol. 2005;36:1154\u201362. https:\/\/doi.org\/10.1016\/j.humpath.2005.07.017.","journal-title":"Hum Pathol"},{"key":"2017_CR121","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3748\/wjg.v22.i9.2779","volume":"22","author":"L Hong","year":"2016","unstructured":"Hong L, et al. New role and molecular mechanism of Gadd45a in hepatic \ufb01brosis. World J Gastroenterol. 2016;22:2779\u201388. https:\/\/doi.org\/10.3748\/wjg.v22.i9.2779.","journal-title":"World J Gastroenterol"},{"key":"2017_CR122","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2174\/156652412800619978","volume":"12","author":"RE Tamura","year":"2012","unstructured":"Tamura RE, et al. GADD45 proteins: central players in tumorigenesis. Curr Mol Med. 2012;12:634\u201351. https:\/\/doi.org\/10.2174\/156652412800619978.","journal-title":"Curr Mol Med"},{"key":"2017_CR123","doi-asserted-by":"publisher","first-page":"15870","DOI":"10.1038\/s41598-024-66838-9","volume":"14","author":"L Cao","year":"2024","unstructured":"Cao L, et al. Pan-cancer analysis and the oncogenic role of Glypican 1 in hepatocellular carcinoma. Sci Rep. 2024;14:15870. https:\/\/doi.org\/10.1038\/s41598-024-66838-9.","journal-title":"Sci Rep"},{"key":"2017_CR124","doi-asserted-by":"publisher","first-page":"E959","DOI":"10.1152\/ajpendo.00202.2012","volume":"303","author":"PA Hecker","year":"2012","unstructured":"Hecker PA, et al. Effects of glucose-6-phosphate dehydrogenase deficiency on the metabolic and cardiac responses to obesogenic or high-fructose diets. Am J Physiol Endocrinol Metab. 2012;303:E959-972. https:\/\/doi.org\/10.1152\/ajpendo.00202.2012.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2017_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.174754","volume":"917","author":"Z Song","year":"2022","unstructured":"Song Z, et al. Glutamic oxaloacetic transaminase 1 as a potential target in human cancer. Eur J Pharmacol. 2022;917:174754. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174754.","journal-title":"Eur J Pharmacol"},{"key":"2017_CR126","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","volume":"15","author":"HK Min","year":"2012","unstructured":"Min HK, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15:665\u201374. https:\/\/doi.org\/10.1016\/j.cmet.2012.04.004.","journal-title":"Cell Metab"},{"key":"2017_CR127","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1152\/physiolgenomics.90339.2008","volume":"37","author":"N Guillen","year":"2009","unstructured":"Guillen N, et al. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiol Genomics. 2009;37:187\u201398. https:\/\/doi.org\/10.1152\/physiolgenomics.90339.2008.","journal-title":"Physiol Genomics"},{"key":"2017_CR128","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa792","volume":"106","author":"TL Stanley","year":"2021","unstructured":"Stanley TL, et al. Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2021;106:e520\u201333. https:\/\/doi.org\/10.1210\/clinem\/dgaa792.","journal-title":"J Clin Endocrinol Metab"},{"key":"2017_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101435","volume":"21","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Identification of IMPA2 as the hub gene associated with colorectal cancer and liver metastasis by integrated bioinformatics analysis. Transl Oncol. 2022;21:101435. https:\/\/doi.org\/10.1016\/j.tranon.2022.101435.","journal-title":"Transl Oncol"},{"key":"2017_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101210","volume":"48","author":"V Azzu","year":"2021","unstructured":"Azzu V, et al. Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression. Mol Metab. 2021;48:101210. https:\/\/doi.org\/10.1016\/j.molmet.2021.101210.","journal-title":"Mol Metab"},{"key":"2017_CR131","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/hep.30559","volume":"69","author":"J Tong","year":"2019","unstructured":"Tong J, et al. Hepatic interferon regulatory factor 6 alleviates liver steatosis and metabolic disorder by transcriptionally suppressing peroxisome proliferator-activated receptor gamma in mice. Hepatology. 2019;69:2471\u201388. https:\/\/doi.org\/10.1002\/hep.30559.","journal-title":"Hepatology"},{"key":"2017_CR132","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s12276-023-01033-w","volume":"55","author":"J Lee","year":"2023","unstructured":"Lee J, et al. LY6D is crucial for lipid accumulation and inflammation in nonalcoholic fatty liver disease. Exp Mol Med. 2023;55:1479\u201391. https:\/\/doi.org\/10.1038\/s12276-023-01033-w.","journal-title":"Exp Mol Med"},{"key":"2017_CR133","doi-asserted-by":"publisher","first-page":"30177","DOI":"10.1074\/jbc.M114.595850","volume":"289","author":"N Soufi","year":"2014","unstructured":"Soufi N, et al. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. J Biol Chem. 2014;289:30177\u201388. https:\/\/doi.org\/10.1074\/jbc.M114.595850.","journal-title":"J Biol Chem"},{"key":"2017_CR134","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1038\/s41388-023-02861-w","volume":"42","author":"F Liu","year":"2023","unstructured":"Liu F, Liao Z, Zhang Z. MYC in liver cancer: mechanisms and targeted therapy opportunities. Oncogene. 2023;42:3303\u201318. https:\/\/doi.org\/10.1038\/s41388-023-02861-w.","journal-title":"Oncogene"},{"key":"2017_CR135","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41419-022-05411-6","volume":"13","author":"C Sequera","year":"2022","unstructured":"Sequera C, et al. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities. Cell Death Dis. 2022;13:994. https:\/\/doi.org\/10.1038\/s41419-022-05411-6.","journal-title":"Cell Death Dis"},{"key":"2017_CR136","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.orcp.2021.01.003","volume":"15","author":"D Meng","year":"2021","unstructured":"Meng D, Pan H, Chen Y, Ding J, Dai Y. Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling). Obes Res Clin Pract. 2021;15:145\u201351. https:\/\/doi.org\/10.1016\/j.orcp.2021.01.003.","journal-title":"Obes Res Clin Pract"},{"key":"2017_CR137","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.gendis.2023.03.021","volume":"11","author":"M Chen","year":"2024","unstructured":"Chen M, Zhu J, Luo H, Mu W, Guo L. The journey towards physiology and pathology: tracing the path of neuregulin 4. Genes Dis. 2024;11:687\u2013700. https:\/\/doi.org\/10.1016\/j.gendis.2023.03.021.","journal-title":"Genes Dis"},{"key":"2017_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2023.111887","volume":"565","author":"D Aibara","year":"2023","unstructured":"Aibara D, Sakaguchi A, Matsusue K. Oxysterol-binding protein-like 3 is a novel target gene of peroxisome proliferator-activated receptor gamma in fatty liver disease. Mol Cell Endocrinol. 2023;565:111887. https:\/\/doi.org\/10.1016\/j.mce.2023.111887.","journal-title":"Mol Cell Endocrinol"},{"key":"2017_CR139","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2147\/DDDT.S310163","volume":"15","author":"J Li","year":"2021","unstructured":"Li J, Guo C, Wu J. The agonists of peroxisome proliferator-activated receptor-gamma for liver fibrosis. Drug Des Devel Ther. 2021;15:2619\u201328. https:\/\/doi.org\/10.2147\/DDDT.S310163.","journal-title":"Drug Des Devel Ther"},{"key":"2017_CR140","doi-asserted-by":"publisher","unstructured":"Phospholipid modifier PLAAT3 links defective PPARgamma-dependent signaling to lipodystrophy. Nat Genet 2023;55:1790\u20131791. https:\/\/doi.org\/10.1038\/s41588-023-01536-2.","DOI":"10.1038\/s41588-023-01536-2"},{"key":"2017_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2025.101331","volume":"98","author":"T Uyama","year":"2025","unstructured":"Uyama T, Sasaki S, Sikder MM, Okada-Iwabu M, Ueda N. The PLAAT family as phospholipid-related enzymes. Prog Lipid Res. 2025;98:101331. https:\/\/doi.org\/10.1016\/j.plipres.2025.101331.","journal-title":"Prog Lipid Res"},{"key":"2017_CR142","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/HMER.S125718","volume":"9","author":"FV Bruschi","year":"2017","unstructured":"Bruschi FV, Tardelli M, Claudel T, Trauner M. PNPLA3 expression and its impact on the liver: current perspectives. Hepat Med. 2017;9:55\u201366. https:\/\/doi.org\/10.2147\/HMER.S125718.","journal-title":"Hepat Med"},{"key":"2017_CR143","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/liv.14402","volume":"40","author":"FV Bruschi","year":"2020","unstructured":"Bruschi FV, Tardelli M, Herac M, Claudel T, Trauner M. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. Liver Int. 2020;40:1098\u2013110. https:\/\/doi.org\/10.1111\/liv.14402.","journal-title":"Liver Int"},{"key":"2017_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102761","author":"Y Takahashi","year":"2023","unstructured":"Takahashi Y, Dungubat E, Kusano H, Fukusato T. Pathology and pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11102761.","journal-title":"Biomedicines"},{"key":"2017_CR145","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado3440","volume":"11","author":"KT Creasy","year":"2025","unstructured":"Creasy KT, et al. Ppp1r3b is a metabolic switch that shifts hepatic energy storage from lipid to glycogen. Sci Adv. 2025;11:eado3440. https:\/\/doi.org\/10.1126\/sciadv.ado3440.","journal-title":"Sci Adv"},{"key":"2017_CR146","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jhep.2018.02.009","volume":"69","author":"N Nishizawa","year":"2018","unstructured":"Nishizawa N, et al. Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice. J Hepatol. 2018;69:110\u201320. https:\/\/doi.org\/10.1016\/j.jhep.2018.02.009.","journal-title":"J Hepatol"},{"key":"2017_CR147","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1124\/dmd.113.050930","volume":"41","author":"EB Yalcin","year":"2013","unstructured":"Yalcin EB, et al. Downregulation of sulfotransferase expression and activity in diseased human livers. Drug Metab Dispos. 2013;41:1642\u201350. https:\/\/doi.org\/10.1124\/dmd.113.050930.","journal-title":"Drug Metab Dispos"},{"key":"2017_CR148","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1194\/jlr.M041988","volume":"55","author":"Y Gao","year":"2014","unstructured":"Gao Y, et al. Upregulation of hepatic VLDLR via PPAR\u03b1 is required for the triglyceride-lowering effect of fenofibrate. J Lipid Res. 2014;55:1622\u201333. https:\/\/doi.org\/10.1194\/jlr.M041988.","journal-title":"J Lipid Res"},{"key":"2017_CR149","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","volume":"8","author":"M Zarei","year":"2018","unstructured":"Zarei M, et al. Hepatic regulation of VLDL receptor by PPARbeta\/delta and FGF21 modulates non-alcoholic fatty liver disease. Mol Metab. 2018;8:117\u201331. https:\/\/doi.org\/10.1016\/j.molmet.2017.12.008.","journal-title":"Mol Metab"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-02017-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:03:03Z","timestamp":1790186583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-02017-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":149,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2017"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-02017-6","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We have no competing interests, nor any conflict of funding to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}